TapewireFind a company

person · Reporting owner

Smith Scott Andrew

Disclosed activity across 6 companies

Tapewire entity
61690
SEC CIK
0001614975

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BioAtla, Inc.BCAB · Entity 879DirectorJune 18, 2025June 18, 2025
CELGENE CORP /DE/CELG · Entity 15781See RemarksFebruary 17, 2018February 20, 2018
F-star Therapeutics, Inc.SBPH · Entity 115726DirectorJune 24, 2020June 25, 2020
TITAN PHARMACEUTICALS INCTTNP · Entity 74432DirectorSeptember 15, 2017September 19, 2017
Viatris IncVTRS · Entity 3277Director · Chief Executive OfficerMarch 06, 2026March 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BioAtla, Inc.

Report date June 18, 2025 · Filed June 18, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect321,550 Reported balance After 2025-06-18 transaction · row 1
1 source row

Row 1 · 2025-06-18 · Grant · Acquired 23,500 · Balance 321,550

F1: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026, or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of Common Stock underlying a time-based restricted stock unit award ("RSU"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026, or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date.

CELGENE CORP /DE/

Report date February 17, 2018 · Filed February 20, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect49,419 Ending reported balance After 2018-02-17 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2018-02-17 · Exercise / conversion · Acquired 7,283 · Balance 51,748

F1: The performance stock units granted to the reporting person on February 13, 2018 vested and settled for shares of the Company's common stock.

Row 2 · 2018-02-17 · Tax withholding · Disposed 2,329 · Balance 49,419

Performance Stock UnitSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-02-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2018-02-17 · Exercise / conversion · Disposed 7,283 · Balance 0

F2: Each performance stock unit represents a contingent right to receive one share of the Company's common stock.

F3: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan.

F1: The performance stock units granted to the reporting person on February 13, 2018 vested and settled for shares of the Company's common stock.

Common StockSEC Table I · non-derivativeIndirect401(k) Plan2,788 Reported balance Holding disclosure · report date 2018-02-17 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 2,788

Filing footnotes · ownership attribution and instrument terms

F1: The performance stock units granted to the reporting person on February 13, 2018 vested and settled for shares of the Company's common stock.

F2: Each performance stock unit represents a contingent right to receive one share of the Company's common stock.

F3: The performance stock units were issued pursuant to the Company's 2017 Stock Incentive Plan.

F-star Therapeutics, Inc.

Report date June 24, 2020 · Filed June 25, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2030-06-23Direct7,500 Reported balance After 2020-06-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2020-06-24 · Grant · Acquired 7,500 · Balance 7,500

F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 24, 2020, the date of the Issuer's 2020 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 24, 2020, the date of the Issuer's 2020 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.

TITAN PHARMACEUTICALS INC

Report date September 15, 2017 · Filed September 19, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2027-09-15Direct10,000 Reported balance After 2017-09-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2017-09-15 · Grant · Acquired 10,000 · Balance 10,000

F1: The option vests in 12 equal monthly installments commencing as of September 1, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in 12 equal monthly installments commencing as of September 1, 2017.

Viatris Inc

Report date March 06, 2026 · Filed March 10, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,329,326 Ending reported balance After 2026-03-06 transaction · row 4
4 source rows · reconciled sequence

Row 1 · 2026-03-06 · Exercise / conversion · Acquired 124,519 · Balance 1,374,576

Row 2 · 2026-03-06 · Tax withholding · Disposed 48,999 · Balance 1,325,577

F1: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on March 6, 2025.

Row 3 · 2026-03-06 · Exercise / conversion · Acquired 6,182 · Balance 1,331,759

F2: Fractional shares have been rounded up in connection with the settlement described in footnote 6 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan.

Row 4 · 2026-03-06 · Tax withholding · Disposed 2,433 · Balance 1,329,326

F3: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 6, 2025.

Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct249,036 Reported balance After 2026-03-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2026-03-06 · Exercise / conversion · Disposed 124,519 · Balance 249,036

F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). 124,519 of the RSUs granted on March 6, 2025 vested on March 6, 2026 and 124,518 will vest on each of March 6, 2027 and March 6, 2028.

Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct256,074 Reported balance After 2026-03-06 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2026-03-06 · Grant · Acquired 256,074 · Balance 256,074

F7: Each RSU represents the right to receive one share of common stock of Viatris. 85,358 of the RSUs granted on March 6, 2026 will vest on each of March 6, 2027, March 6, 2028, and March 6, 2029.

Dividend Equivalent UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct12,362 Reported balance After 2026-03-06 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2026-03-06 · Exercise / conversion · Disposed 6,181.4237 · Balance 12,362

F5: Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11.

F6: Represents DEUs that accrued with respect to the RSUs previously granted on March 6, 2025 and vest on the same schedule as the underlying RSUs.

Filing footnotes · ownership attribution and instrument terms

F1: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on March 6, 2025.

F2: Fractional shares have been rounded up in connection with the settlement described in footnote 6 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan.

F3: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 6, 2025.

F4: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). 124,519 of the RSUs granted on March 6, 2025 vested on March 6, 2026 and 124,518 will vest on each of March 6, 2027 and March 6, 2028.

F5: Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11.

F6: Represents DEUs that accrued with respect to the RSUs previously granted on March 6, 2025 and vest on the same schedule as the underlying RSUs.

F7: Each RSU represents the right to receive one share of common stock of Viatris. 85,358 of the RSUs granted on March 6, 2026 will vest on each of March 6, 2027, March 6, 2028, and March 6, 2029.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Apexigen, Inc.

Report date August 23, 2023 · Filed August 25, 2023

Section 16 reporting ended · disclosed 2023-08-25. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.94 · Expires 2029-11-08Direct0 Reported balance After 2023-08-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-08-23 · Disposition to issuer · Disposed 34,084 · Balance 0

F1: The shares subject to the option vest in 48 equal monthly installments beginning on September 16, 2019. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $40.24 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2032-09-29Direct0 Reported balance After 2023-08-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2023-08-23 · Disposition to issuer · Disposed 100,000 · Balance 0

F2: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option vest in 48 equal monthly installments beginning on September 16, 2019. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $40.24 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.

F2: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 03, 2024 Filed Mar 5, 2024 20:01 UTC Viatris Inc VTRS · Entity 3277 Exercise / conversionCommon Stock 4,898 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-026620 · ownership.xml · nonDerivative · entry 3

Smith Scott Andrew · CIK 0001614975 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,278

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: Fractional shares have been rounded up in connection with the settlement described in footnote 6 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan.

Read SEC document
March 03, 2024 Filed Mar 5, 2024 20:01 UTC Viatris Inc VTRS · Entity 3277 Tax withholdingCommon Stock 53,449 $12.59 $672,922.91
Disclosure

SEC source: 0000950170-24-026620 · ownership.xml · nonDerivative · entry 2

Smith Scott Andrew · CIK 0001614975 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,380

F1 · shares: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on April 1, 2023.

Read SEC document
March 03, 2024 Filed Mar 5, 2024 20:01 UTC Viatris Inc VTRS · Entity 3277 Exercise / conversionCommon Stock 135,829 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-026620 · ownership.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,829

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
February 29, 2024 Filed Mar 1, 2024 16:22 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 2,181 $2.70 $5,888.70
Disclosure

SEC source: 0001209191-24-004161 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 294,636

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
January 31, 2024 Filed Feb 1, 2024 20:32 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 2,181 $1.92 $4,187.52
Disclosure

SEC source: 0001209191-24-002594 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 296,817

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
December 31, 2023 Filed Jan 3, 2024 20:17 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $2.46 $4,405.86
Disclosure

SEC source: 0001209191-24-000598 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 298,998

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
November 30, 2023 Filed Dec 1, 2023 16:46 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $1.77 $3,170.07
Disclosure

SEC source: 0001209191-23-057086 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,789

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
October 31, 2023 Filed Nov 1, 2023 21:17 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $1.47 $2,632.77
Disclosure

SEC source: 0001209191-23-054062 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 302,580

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
September 30, 2023 Filed Oct 2, 2023 18:03 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $1.70 $3,044.70
Disclosure

SEC source: 0001209191-23-051180 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 304,371

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
August 31, 2023 Filed Sep 1, 2023 20:03 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $2.51 $4,495.41
Disclosure

SEC source: 0001209191-23-048033 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 306,162

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
August 23, 2023 Filed Aug 25, 2023 19:37 UTC Apexigen, Inc. APGN · Entity 110214 Disposition to issuerStock Option (right to buy) · Derivative 100,000 Not disclosed Strike: $2.65 Not disclosed
Disclosure

SEC source: 0001209191-23-047452 · doc4.xml · derivative · entry 2

Smith Scott Andrew · CIK 0001614975 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 100,000 shares

Expires 2032-09-29

F2 · price: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.

F2 · derivative.exercise_date: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.

Read SEC document
August 23, 2023 Filed Aug 25, 2023 19:37 UTC Apexigen, Inc. APGN · Entity 110214 Disposition to issuerStock Option (right to buy) · Derivative 34,084 Not disclosed Strike: $6.94 Not disclosed
Disclosure

SEC source: 0001209191-23-047452 · doc4.xml · derivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 34,084 shares

Expires 2029-11-08

F1 · price: The shares subject to the option vest in 48 equal monthly installments beginning on September 16, 2019. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $40.24 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.

F1 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on September 16, 2019. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $40.24 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.

Read SEC document
July 31, 2023 Filed Aug 1, 2023 17:41 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $2.99 $5,355.09
Disclosure

SEC source: 0001209191-23-044048 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 307,953

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
June 30, 2023 Filed Jul 3, 2023 17:43 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $3.00 $5,373.00
Disclosure

SEC source: 0001209191-23-040666 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 309,744

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
June 14, 2023 Filed Jun 15, 2023 18:43 UTC BioAtla, Inc. BCAB · Entity 879 GrantStock Option (Right to Buy) · Derivative 5,895 $0.00 Strike: $3.55 $0.00
Disclosure

SEC source: 0001209191-23-037549 · doc4.xml · derivative · entry 2

Smith Scott Andrew · CIK 0001614975 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,895

Underlying: Common Stock · 5,895 shares

Expires 2033-06-14

F2 · derivative.exercise_date: Fully vested and exercisable.

Read SEC document
June 14, 2023 Filed Jun 15, 2023 18:43 UTC BioAtla, Inc. BCAB · Entity 879 GrantStock Option (Right to Buy) · Derivative 50,000 $0.00 Strike: $3.55 $0.00
Disclosure

SEC source: 0001209191-23-037549 · doc4.xml · derivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2033-06-14

F1 · derivative.exercise_date: 100% of the total number of shares subject to the option shall vest and become exercisable on the earlier of (a) June 14, 2024 or (b) the day before the next annual meeting of stockholders, subject to the reporting person continuing to provide services through the vesting date.

Read SEC document
May 31, 2023 Filed Jun 1, 2023 20:24 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $3.15 $5,641.65
Disclosure

SEC source: 0001209191-23-033470 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 311,535

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
April 30, 2023 Filed May 2, 2023 18:01 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $3.37 $6,035.67
Disclosure

SEC source: 0001209191-23-026658 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 313,326

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
April 01, 2023 Filed Apr 4, 2023 18:00 UTC Viatris Inc VTRS · Entity 3277 GrantRestricted Stock Units · Derivative 407,485 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000950170-23-011813 · ownership.xml · derivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 407,485

Underlying: Common Stock · 407,485 shares

Expires not disclosed

F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. 135,829 of the RSUs granted on April 1, 2023 will vest on March 3, 2024 and 135,828 will vest on each of March 3, 2025 and March 3, 2026.

F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. 135,829 of the RSUs granted on April 1, 2023 will vest on March 3, 2024 and 135,828 will vest on each of March 3, 2025 and March 3, 2026.

Read SEC document
March 31, 2023 Filed Apr 3, 2023 20:01 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $2.68 $4,799.88
Disclosure

SEC source: 0001209191-23-022427 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director · Former President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 315,117

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
February 28, 2023 Filed Mar 1, 2023 18:33 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $2.98 $5,337.18
Disclosure

SEC source: 0001209191-23-014294 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director · Former President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 316,908

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
February 10, 2023 Filed Mar 1, 2023 18:33 UTC BioAtla, Inc. BCAB · Entity 879 GrantEmployee Stock Option (right to buy) · Derivative 350,000 $0.00 Strike: $3.65 $0.00
Disclosure

SEC source: 0001209191-23-014294 · doc4.xml · derivative · entry 2

Smith Scott Andrew · CIK 0001614975 · Director · Former President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires 2033-02-10

F2 · derivative.exercise_date: The option vests over a period of four years, with 25% of the shares underlying the option vesting on the first anniversary of the date of grant, and the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued service to the company through the applicable vesting dates.

Read SEC document
January 31, 2023 Filed Feb 2, 2023 19:09 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 2,181 $3.79 $8,265.99
Disclosure

SEC source: 0001209191-23-006433 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 318,699

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
December 31, 2022 Filed Jan 3, 2023 17:07 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $8.25 $14,775.75
Disclosure

SEC source: 0001209191-23-000318 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 320,880

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
November 30, 2022 Filed Dec 1, 2022 20:58 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $11.01 $19,718.91
Disclosure

SEC source: 0001209191-22-059264 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 322,671

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
October 31, 2022 Filed Nov 1, 2022 19:54 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $6.89 $12,339.99
Disclosure

SEC source: 0001209191-22-055166 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 324,462

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
September 30, 2022 Filed Oct 4, 2022 19:53 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $7.70 $13,790.70
Disclosure

SEC source: 0001209191-22-052558 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 326,253

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
September 29, 2022 Filed Oct 3, 2022 18:34 UTC Apexigen, Inc. APGN · Entity 110214 GrantStock Option (right to buy) · Derivative 100,000 $0.00 Strike: $2.65 $0.00
Disclosure

SEC source: 0001209191-22-051953 · doc4.xml · derivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2032-09-29

F1 · derivative.exercise_date: The shares subject to the option vest in three equal annual installments beginning on July 29, 2023.

Read SEC document
August 31, 2022 Filed Sep 1, 2022 18:47 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $8.71 $15,599.61
Disclosure

SEC source: 0001209191-22-048363 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 328,044

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
July 31, 2022 Filed Aug 1, 2022 18:24 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $3.40 $6,089.40
Disclosure

SEC source: 0001209191-22-043741 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 329,835

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
June 30, 2022 Filed Jul 1, 2022 17:23 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $2.85 $5,104.35
Disclosure

SEC source: 0001209191-22-040322 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 331,626

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
May 31, 2022 Filed Jun 3, 2022 18:04 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $2.41 $4,316.31
Disclosure

SEC source: 0001209191-22-034299 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 333,417

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
April 30, 2022 Filed May 6, 2022 16:58 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $3.48 $6,232.68
Disclosure

SEC source: 0001209191-22-027629 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 335,208

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
March 31, 2022 Filed Apr 4, 2022 21:13 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $5.00 $8,955.00
Disclosure

SEC source: 0001209191-22-022743 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 336,999

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
February 28, 2022 Filed Mar 4, 2022 17:03 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 1,791 $6.48 $11,605.68
Disclosure

SEC source: 0001209191-22-016367 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 338,790

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
February 22, 2022 Filed Feb 24, 2022 21:21 UTC BioAtla, Inc. BCAB · Entity 879 GrantEmployee Stock Option (right to buy) · Derivative 200,000 $0.00 Strike: $6.66 $0.00
Disclosure

SEC source: 0001209191-22-012946 · doc4.xml · derivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2032-02-22

F1 · derivative.exercise_date: The option vests over a period of four years, with 25% of the shares underlying the option vesting on February 22, 2023, the first anniversary of the date of grant, and the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting dates.

Read SEC document
January 31, 2022 Filed Feb 2, 2022 17:43 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 2,181 $9.56 $20,850.36
Disclosure

SEC source: 0001209191-22-006500 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 340,581

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
December 31, 2021 Filed Jan 5, 2022 20:33 UTC BioAtla, Inc. BCAB · Entity 879 Tax withholdingCommon Stock 2,894 $19.63 $56,809.22
Disclosure

SEC source: 0001209191-22-002040 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 342,762

F1 · kind: This transaction is not a sale of shares by the Reporting Person. Instead, this represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the vesting and net settlement of previously reported restricted stock units.

Read SEC document
December 02, 2021 Filed Dec 7, 2021 17:41 UTC BioAtla, Inc. BCAB · Entity 879 SaleCommon Stock 59 $22.47 $1,325.79
Disclosure

SEC source: 0001209191-21-068385 · doc4.xml · nonDerivative · entry 8

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 345,656

F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs.

F9 · price: The range of prices for the shares of Common Stock is from $22.40 to $22.51. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price.

Read SEC document
December 02, 2021 Filed Dec 7, 2021 17:41 UTC BioAtla, Inc. BCAB · Entity 879 SaleCommon Stock 2,925 $21.74 $63,592.43
Disclosure

SEC source: 0001209191-21-068385 · doc4.xml · nonDerivative · entry 7

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 345,715

F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs.

F8 · price: The range of prices for the shares of Common Stock is from $21.40 to $22.37. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price.

Read SEC document
December 01, 2021 Filed Dec 7, 2021 17:41 UTC BioAtla, Inc. BCAB · Entity 879 SaleCommon Stock 76 $24.22 $1,841.02
Disclosure

SEC source: 0001209191-21-068385 · doc4.xml · nonDerivative · entry 6

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 348,640

F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs.

F7 · price: The range of prices for the shares of Common Stock is from $23.80 to $24.68. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price.

Read SEC document
December 01, 2021 Filed Dec 7, 2021 17:41 UTC BioAtla, Inc. BCAB · Entity 879 SaleCommon Stock 350 $23.27 $8,143.10
Disclosure

SEC source: 0001209191-21-068385 · doc4.xml · nonDerivative · entry 5

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 348,716

F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs.

F6 · price: The range of prices for the shares of Common Stock is from $22.79 to $23.77. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price.

Read SEC document
December 01, 2021 Filed Dec 7, 2021 17:41 UTC BioAtla, Inc. BCAB · Entity 879 SaleCommon Stock 202 $22.19 $4,481.57
Disclosure

SEC source: 0001209191-21-068385 · doc4.xml · nonDerivative · entry 4

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 349,066

F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs.

F5 · price: The range of prices for the shares of Common Stock is from $21.79 to $22.73. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price.

Read SEC document
November 30, 2021 Filed Dec 7, 2021 17:41 UTC BioAtla, Inc. BCAB · Entity 879 SaleCommon Stock 74 $25.38 $1,878.05
Disclosure

SEC source: 0001209191-21-068385 · doc4.xml · nonDerivative · entry 3

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 349,268

F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs.

F4 · price: The range of prices for the shares of Common Stock is from $25.30 to $25.38. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price.

Read SEC document
November 30, 2021 Filed Dec 7, 2021 17:41 UTC BioAtla, Inc. BCAB · Entity 879 SaleCommon Stock 210 $24.68 $5,181.96
Disclosure

SEC source: 0001209191-21-068385 · doc4.xml · nonDerivative · entry 2

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 349,342

F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs.

F3 · price: The range of prices for the shares of Common Stock is from $24.33 to $25.25. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price.

Read SEC document
November 30, 2021 Filed Dec 7, 2021 17:41 UTC BioAtla, Inc. BCAB · Entity 879 SaleCommon Stock 194 $24.00 $4,655.42
Disclosure

SEC source: 0001209191-21-068385 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 349,552

F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs.

F2 · price: The range of prices for the shares of Common Stock is from $23.33 to $24.32. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price.

Read SEC document
November 29, 2021 Filed Dec 6, 2021 20:42 UTC BioAtla, Inc. BCAB · Entity 879 SaleCommon Stock 399 $23.89 $9,532.11
Disclosure

SEC source: 0001209191-21-068213 · doc4.xml · nonDerivative · entry 1

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 349,746

F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs.

F2 · price: The range of prices for the shares of Common Stock is from $23.75 to $24.11. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price.

Read SEC document
November 24, 2021 Filed Nov 30, 2021 20:06 UTC BioAtla, Inc. BCAB · Entity 879 SaleCommon Stock 133 $25.77 $3,427.54
Disclosure

SEC source: 0001209191-21-067219 · doc4.xml · nonDerivative · entry 6

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,145

F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs.

F7 · price: The range of prices for the shares of Common Stock is from $25.57 to $26.14. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price.

Read SEC document
November 24, 2021 Filed Nov 30, 2021 20:06 UTC BioAtla, Inc. BCAB · Entity 879 SaleCommon Stock 160 $25.00 $3,999.84
Disclosure

SEC source: 0001209191-21-067219 · doc4.xml · nonDerivative · entry 5

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,278

F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs.

F6 · price: The range of prices for the shares of Common Stock is from $24.48 to $25.42. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price.

Read SEC document
November 24, 2021 Filed Nov 30, 2021 20:06 UTC BioAtla, Inc. BCAB · Entity 879 SaleCommon Stock 173 $24.05 $4,161.17
Disclosure

SEC source: 0001209191-21-067219 · doc4.xml · nonDerivative · entry 4

Smith Scott Andrew · CIK 0001614975 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,438

F1 · kind: Represents shares of the Issuer's common stock sold by the reporting person to cover taxes due upon the release and settlement of the vested RSUs.

F5 · price: The range of prices for the shares of Common Stock is from $23.48 to $24.32. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.